A clinical scoring system to predict long-term arthralgia in Chikungunya disease: A cohort study.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
11
11
2019
accepted:
09
06
2020
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
21
8
2020
Statut:
epublish
Résumé
Chikungunya virus (CHIKV) has caused worldwide epidemics that impose a major burden on health systems. Approximately half of infected individuals develop chronic debilitating arthralgia, affecting their quality of life. Here, we identified the relevant clinical and demographic variables in the acute phase of CHIKV infection prospectively linked to chronic arthralgia to elaborate a prognostic scoring system. Acute CHIKV infection cases (n = 134) confirmed by serology or molecular test were examined <10 days of disease onset and followed for one year to evaluate for disease progression. Potential risk factors for chronic arthralgia were evaluated by multivariate analysis to develop a prognostic scoring system, which was subsequently tested in an independent validation cohort consisting of 42 individuals. A total of 107 out of 134 (80%) acute CHIKV-confirmed cases from the derivation cohort were re-examined one year after enrollment. Chronic arthralgia post-CHIKV infection was diagnosed in 64 (60%). Five of the 12 parameters evaluated in the acute phase were statistically associated with persistent arthralgia and were further tested by Bayesian analysis. These variables were weighted to yield a prognosis score denominated SHERA (Sex, Hypertension, Edema, Retroocular pain, Age), which exhibited 81.3% accuracy in predicting long-term arthralgia post-CHIKV infection in the derivation cohort, and 76.5% accuracy in the validation cohort. The simplified and externally validated prognostic scoring system, SHERA, is a useful method to screen acutely CHIKV-infected patients at elevated risk of chronic arthralgia who will benefit from specific interventions. This tool could guide public health policies, particularly in resource-constrained settings.
Sections du résumé
BACKGROUND
Chikungunya virus (CHIKV) has caused worldwide epidemics that impose a major burden on health systems. Approximately half of infected individuals develop chronic debilitating arthralgia, affecting their quality of life. Here, we identified the relevant clinical and demographic variables in the acute phase of CHIKV infection prospectively linked to chronic arthralgia to elaborate a prognostic scoring system.
METHODS
Acute CHIKV infection cases (n = 134) confirmed by serology or molecular test were examined <10 days of disease onset and followed for one year to evaluate for disease progression. Potential risk factors for chronic arthralgia were evaluated by multivariate analysis to develop a prognostic scoring system, which was subsequently tested in an independent validation cohort consisting of 42 individuals.
RESULTS
A total of 107 out of 134 (80%) acute CHIKV-confirmed cases from the derivation cohort were re-examined one year after enrollment. Chronic arthralgia post-CHIKV infection was diagnosed in 64 (60%). Five of the 12 parameters evaluated in the acute phase were statistically associated with persistent arthralgia and were further tested by Bayesian analysis. These variables were weighted to yield a prognosis score denominated SHERA (Sex, Hypertension, Edema, Retroocular pain, Age), which exhibited 81.3% accuracy in predicting long-term arthralgia post-CHIKV infection in the derivation cohort, and 76.5% accuracy in the validation cohort.
CONCLUSIONS
The simplified and externally validated prognostic scoring system, SHERA, is a useful method to screen acutely CHIKV-infected patients at elevated risk of chronic arthralgia who will benefit from specific interventions. This tool could guide public health policies, particularly in resource-constrained settings.
Identifiants
pubmed: 32693402
doi: 10.1371/journal.pntd.0008467
pii: PNTD-D-19-01908
pmc: PMC7373495
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008467Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Epidemiol Infect. 2012 May;140(5):842-50
pubmed: 21767452
Mem Inst Oswaldo Cruz. 2017 Aug;112(8):523-531
pubmed: 28767976
Lancet. 2007 Dec 1;370(9602):1840-6
pubmed: 18061059
PLoS Curr. 2016 Feb 01;8:
pubmed: 27330849
PLoS Negl Trop Dis. 2009;3(3):e389
pubmed: 19274071
PLoS Negl Trop Dis. 2013;7(3):e2137
pubmed: 23556021
Epidemiol Infect. 2009 Apr;137(4):534-41
pubmed: 18694529
Clin Infect Dis. 2008 Aug 15;47(4):469-75
pubmed: 18611153
J Intern Med. 2003 Jun;253(6):643-52
pubmed: 12755960
Trans R Soc Trop Med Hyg. 2015 Dec;109(12):793-802
pubmed: 26626342
J Infect. 2012 Aug;65(2):165-72
pubmed: 22522292
Clin Infect Dis. 2017 Jul 1;65(1):133-140
pubmed: 28379375
Rev Soc Bras Med Trop. 2018 Jan-Feb;51(1):63-65
pubmed: 29513844
Trans R Soc Trop Med Hyg. 2019 Apr 1;113(4):221-226
pubmed: 30551206
BMC Musculoskelet Disord. 2014 Jul 24;15:249
pubmed: 25059583
J Vector Borne Dis. 2009 Mar;46(1):26-35
pubmed: 19326705
Emerg Infect Dis. 2017 Oct;23(10):1742-1744
pubmed: 28930031
PLoS Negl Trop Dis. 2017 Oct 9;11(10):e0005987
pubmed: 28991920
Arthritis Res Ther. 2013 Jan 09;15(1):R9
pubmed: 23302155
Med Mal Infect. 2015 Jul;45(7):243-63
pubmed: 26119684
J Rheumatol. 2016 Feb;43(2):440-4
pubmed: 26669921
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148838
Rheumatology (Oxford). 2012 Jul;51(7):1315-22
pubmed: 22427407
Sci Rep. 2016 May 16;6:26097
pubmed: 27180811
Postgrad Med J. 2013 Aug;89(1054):440-7
pubmed: 23645664
Int J Infect Dis. 2017 May;58:69-76
pubmed: 28288924
N Engl J Med. 2007 Feb 22;356(8):769-71
pubmed: 17314335
Open Forum Infect Dis. 2018 Jan 03;5(1):ofx234
pubmed: 29308412